Albendazole is NOT a recommended treatment for scabies
Albendazole is not indicated for scabies treatment and should not be used as standard therapy. The FDA-approved indications for albendazole are limited to neurocysticercosis and hydatid disease only 1. Current clinical guidelines for scabies management do not include albendazole as a recommended or alternative treatment option 2.
Standard Treatment Recommendations for Scabies
First-Line Therapy
- Permethrin 5% cream: Apply to entire body from neck down, wash off after 8-14 hours 2
- Oral ivermectin: 200 μg/kg as a single dose, repeat in 14 days 2
Permethrin is the preferred topical agent due to its effectiveness, safety profile, and lower cost compared to ivermectin 2. Ivermectin should be taken with food to increase bioavailability and epidermal penetration 2.
Alternative Regimens (when first-line fails or is contraindicated)
- Lindane 1%: Apply for 8 hours, but only if other therapies have failed due to neurotoxicity risk 2
- Contraindicated in: Children <10 years, pregnant/lactating women, extensive dermatitis, immediately after bathing 2
Special Populations
Crusted (Norwegian) Scabies
This severe form requires combination therapy 2:
- Topical permethrin 5% OR benzyl benzoate 5%: Daily application for 7 days, then twice weekly until cure
- PLUS oral ivermectin 200 μg/kg: Days 1,2,8,9, and 15
- Severe cases may require additional ivermectin on days 22 and 29 2
- Avoid lindane due to neurotoxicity risk with heavy application 2
Pregnant/Lactating Women and Young Children
- Permethrin is preferred 2
- Ivermectin safety not established in children <15 kg 2
- Children <10 years should not receive lindane 2
HIV/Immunocompromised Patients
- Uncomplicated scabies: Same regimens as immunocompetent patients 2
- Higher risk for crusted scabies: Manage in consultation with specialist 2
Why Albendazole Should Not Be Used
While two case reports describe albendazole use for crusted scabies 3, 4, these represent off-label, anecdotal use without supporting clinical trial evidence. The proposed mechanism involves larvicidal effects 3, but:
- No guideline support: Major STD treatment guidelines from CDC do not mention albendazole for scabies 2
- Significant toxicity concerns: Bone marrow suppression, aplastic anemia, agranulocytosis, hepatotoxicity 1
- Required monitoring: Blood counts and liver enzymes every 2 weeks 1
- Pregnancy risk: Category C with documented embryotoxicity and skeletal malformations 1
- Superior alternatives exist: Permethrin and ivermectin have established efficacy and safety profiles
Essential Management Considerations
Environmental Decontamination
- Machine-wash or dry-clean bedding and clothing, OR remove from body contact for 72 hours 2
- Fumigation is unnecessary 2
Contact Management
- Examine and treat all sexual, close personal, or household contacts within the preceding month 2
Follow-Up
- Pruritus may persist up to 2 weeks after successful treatment 2
- Consider retreatment at 2 weeks if symptoms persist or live mites observed 2
- Use alternative regimen if initial treatment fails 2
Common Pitfalls
- Improper topical application technique
- Failure to treat contacts simultaneously
- Incomplete environmental decontamination
- Premature assessment of treatment failure (before 2 weeks)
- Using lindane in contraindicated populations
Institutional Outbreaks
For nursing homes, hospitals, or residential facilities, treat the entire at-risk population simultaneously 2. Ivermectin may be preferred in these settings, especially if topical therapy fails 2. Manage in consultation with a specialist 2.